Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Androgen Antagonists
  • Antigens, Surface
  • Bone Neoplasms
  • Drug Resistance, Neoplasm
  • Glutamate Carboxypeptidase II
  • Immunoconjugates
  • Prostatic Neoplasms

abstract

  • Therapeutic doses of MLN2704 can be administered safely on a repetitive basis. An MTD was not defined. MLN2704 is being administered at more frequent intervals in ongoing trials to determine an optimal dosing schedule.

publication date

  • September 22, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2007.15.0532

PubMed ID

  • 18362364

Additional Document Info

start page

  • 2147

end page

  • 54

volume

  • 26

number

  • 13